MorphoSys sends its Constellation drug work to Germany, shuttering US R&D and taking a $250M hit in reorganization
When MorphoSys swooped in with a $1.7 billion deal to buy Constellation Pharmaceuticals last year, then CEO Jigar Raythatha paid tribute to the nearly 200 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
